1887

Abstract

Vaccination with live attenuated simian immunodeficiency virus (SIV) in non-human primate species provides a means of characterizing the protective processes of retroviral superinfection and may lead to novel advances of human immunodeficiency virus (HIV)/AIDS vaccine design. The minimally attenuated SIVmacC8 vaccine has been demonstrated to elicit early potent protection against pathogenic rechallenge with genetically diverse viral isolates in cynomolgus macaques (). In this study, we have characterized further the biological breadth of this vaccine protection by assessing the ability of both the -disrupted SIVmacC8 and its -intact counterpart SIVmacJ5 viruses to prevent superinfection with the macrophage/neurotropic SIVmac239/17E-Fr (SIVmac17E-Fr) isolate. Inoculation with either SIVmacC8 or SIVmacJ5 and subsequent detailed characterization of the viral replication kinetics revealed a wide range of virus–host outcomes. Both -disrupted and -intact immunizing viruses were able to prevent establishment of SIVmac17E-Fr in peripheral blood and secondary lymphoid tissues. Differences in virus kinetics, indicative of an active process, identified uncontrolled replication in one macaque which although able to prevent SIVmac17E-Fr superinfection led to extensive neuropathological complications. The ability to prevent a biologically heterologous, CD4-independent/CCR5 viral isolate and the macrophage-tropic SIVmac316 strain from establishing infection supports the hypothesis that direct target cell blocking is unlikely to be a central feature of live lentivirus vaccination. These data provide further evidence to demonstrate that inoculation of a live retroviral vaccine can deliver broad spectrum protection against both macrophage-tropic as well as lymphocytotropic viruses. These data add to our knowledge of live attenuated SIV vaccines but further highlight potential safety concerns of vaccinating with a live retrovirus.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/vir.0.000135
2015-07-01
2019-10-14
Loading full text...

Full text loading...

/deliver/fulltext/jgv/96/7/1918.html?itemId=/content/journal/jgv/10.1099/vir.0.000135&mimeType=html&fmt=ahah

References

  1. Almond N., Kent K., Cranage M., Rud E., Clarke B., Stott E.J.. ( 1995;). Protection by attenuated simian immunodeficiency virus in macaques against challenge with virus-infected cells. Lancet 345: 1342–1344 [CrossRef] [PubMed].
    [Google Scholar]
  2. Almond N., Rose J., Sangster R., Silvera P., Stebbings R., Walker B., Stott E.J.. ( 1997;). Mechanisms of protection induced by attenuated simian immunodeficiency virus. I. Protection cannot be transferred with immune serum. J Gen Virol 78: 1919–1922 [PubMed].
    [Google Scholar]
  3. Berry N., Stebbings R., Ferguson D., Ham C., Alden J., Brown S., Jenkins A., Lines J., Duffy L., other authors. ( 2008;). Resistance to superinfection by a vigorously replicating, uncloned stock of simian immunodeficiency virus (SIVmac251) stimulates replication of a live attenuated virus vaccine (SIVmacC8). J Gen Virol 89: 2240–2251 [CrossRef] [PubMed].
    [Google Scholar]
  4. Berry N., Ham C., Mee E.T., Rose N.J., Mattiuzzo G., Jenkins A., Page M., Elsley W., Robinson M., other authors. ( 2011;). Early potent protection against heterologous SIVsmE660 challenge following live attenuated SIV vaccination in Mauritian cynomolgus macaques. PLoS One 6: e23092 [CrossRef] [PubMed].
    [Google Scholar]
  5. Cantó-Nogués C., Jones S., Sangster R., Silvera P., Hull R., Cook R., Hall G., Walker B., Stott E.J., other authors. ( 2001;). In situ hybridization and immunolabelling study of the early replication of simian immunodeficiency virus (SIVmacJ5) in vivo. J Gen Virol 82: 2225–2234 [PubMed].
    [Google Scholar]
  6. Clarke S., Almond N., Berry N.. ( 2003;). Simian immunodeficiency virus Nef gene regulates the production of 2-LTR circles in vivo. Virology 306: 100–108 [CrossRef] [PubMed].
    [Google Scholar]
  7. Clarke S., Berry N., Ham C., Alden J., Almond N., Ferguson D.. ( 2012;). Neuropathology of wild-type and nef-attenuated T cell tropic simian immunodeficiency virus (SIVmac32H) and macrophage tropic neurovirulent SIVmac17E-Fr in cynomolgus macaques. J Neurovirol 18: 100–112 [CrossRef] [PubMed].
    [Google Scholar]
  8. Clements J.E., Babas T., Mankowski J.L., Suryanarayana K., Piatak M. Jr, Tarwater P.M., Lifson J.D., Zink M.C.. ( 2002;). The central nervous system as a reservoir for simian immunodeficiency virus (SIV): steady-state levels of SIV DNA in brain from acute through asymptomatic infection. J Infect Dis 186: 905–913 [CrossRef] [PubMed].
    [Google Scholar]
  9. Connor R.I., Montefiori D.C., Binley J.M., Moore J.P., Bonhoeffer S., Gettie A., Fenamore E.A., Sheridan K.E., Ho D.D., other authors. ( 1998;). Temporal analyses of virus replication, immune responses, and efficacy in rhesus macaques immunized with a live, attenuated simian immunodeficiency virus vaccine. J Virol 72: 7501–7509 [PubMed].
    [Google Scholar]
  10. Daniel M.D., Kirchhoff F., Czajak S.C., Sehgal P.K., Desrosiers R.C.. ( 1992;). Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene. Science 258: 1938–1941 [CrossRef] [PubMed].
    [Google Scholar]
  11. Edinger A.L., Mankowski J.L., Doranz B.J., Margulies B.J., Lee B., Rucker J., Sharron M., Hoffman T.L., Berson J.F., other authors. ( 1997;). CD4-independent, CCR5-dependent infection of brain capillary endothelial cells by a neurovirulent simian immunodeficiency virus strain. Proc Natl Acad Sci U S A 94: 14742–14747 [CrossRef] [PubMed].
    [Google Scholar]
  12. Ferguson D., Mattiuzzo G., Ham C., Stebbings R., Li B., Rose N.J., Mee E.T., Smith D., Page M., other authors. ( 2014;). Early biodistribution and persistence of a protective live attenuated SIV vaccine elicits localised innate responses in multiple lymphoid tissues. PLoS One 9: e104390 [CrossRef] [PubMed].
    [Google Scholar]
  13. Flaherty M.T., Hauer D.A., Mankowski J.L., Zink M.C., Clements J.E.. ( 1997;). Molecular and biological characterization of a neurovirulent molecular clone of simian immunodeficiency virus. J Virol 71: 5790–5798 [PubMed].
    [Google Scholar]
  14. Fukazawa Y., Park H., Cameron M.J., Lefebvre F., Lum R., Coombes N., Mahyari E., Hagen S.I., Bae J.Y., other authors. ( 2012;). Lymph node T cell responses predict the efficacy of live attenuated SIV vaccines. Nat Med 18: 1673–1681 [CrossRef] [PubMed].
    [Google Scholar]
  15. Johnson R.P., Lifson J.D., Czajak S.C., Cole K.S., Manson K.H., Glickman R., Yang J., Montefiori D.C., Montelaro R., other authors. ( 1999;). Highly attenuated vaccine strains of simian immunodeficiency virus protect against vaginal challenge: inverse relationship of degree of protection with level of attenuation. J Virol 73: 4952–4961 [PubMed].
    [Google Scholar]
  16. Koff W.C., Johnson P.R., Watkins D.I., Burton D.R., Lifson J.D., Hasenkrug K.J., McDermott A.B., Schultz A., Zamb T.J., other authors. ( 2006;). HIV vaccine design: insights from live attenuated SIV vaccines. Nat Immunol 7: 19–23 [CrossRef] [PubMed].
    [Google Scholar]
  17. Li B., Berry N., Ham C., Ferguson D., Smith D., Hall J., Page M., Quartey-Papafio R., Elsley W., other authors. ( 2011;). Vaccination with live attenuated simian immunodeficiency virus causes dynamic changes in intestinal CD4+CCR5+T cells. Retrovirology 8: 8 [CrossRef] [PubMed].
    [Google Scholar]
  18. Lifson J.D., Nowak M.A., Goldstein S., Rossio J.L., Kinter A., Vasquez G., Wiltrout T.A., Brown C., Schneider D., other authors. ( 1997;). The extent of early viral replication is a critical determinant of the natural history of simian immunodeficiency virus infection. J Virol 71: 9508–9514 [PubMed].
    [Google Scholar]
  19. Mankowski J.L., Flaherty M.T., Spelman J.P., Hauer D.A., Didier P.J., Amedee A.M., Murphey-Corb M., Kirstein L.M., Muñoz A., other authors. ( 1997;). Pathogenesis of simian immunodeficiency virus encephalitis: viral determinants of neurovirulence. J Virol 71: 6055–6060 [PubMed].
    [Google Scholar]
  20. Manoussaka M., Berry N., Ferguson D., Stebbings R., Robinson M., Ham C., Page M., Li B., Das A., other authors. ( 2013;). Conditionally-live attenuated SIV upregulates global T effector memory cell frequency under replication permissive conditions. Retrovirology 10: 59 [CrossRef] [PubMed].
    [Google Scholar]
  21. Mansfield K., Lang S.M., Gauduin M.C., Sanford H.B., Lifson J.D., Johnson R.P., Desrosiers R.C.. ( 2008;). Vaccine protection by live, attenuated simian immunodeficiency virus in the absence of high-titer antibody responses and high-frequency cellular immune responses measurable in the periphery. J Virol 82: 4135–4148 [CrossRef] [PubMed].
    [Google Scholar]
  22. Micci L., Alvarez X., Iriele R.I., Ortiz A.M., Ryan E.S., McGary C.S., Deleage C., McAtee B.B., He T., other authors. ( 2014;). CD4 depletion in SIV-infected macaques results in macrophage and microglia infection with rapid turnover of infected cells. PLoS Pathog 10: e1004467 [CrossRef] [PubMed].
    [Google Scholar]
  23. Mori K., Ringler D.J., Desrosiers R.C.. ( 1993;). Restricted replication of simian immunodeficiency virus strain 239 in macrophages is determined by env but is not due to restricted entry. J Virol 67: 2807–2814 [PubMed].
    [Google Scholar]
  24. Mori K., Rosenzweig M., Desrosiers R.C.. ( 2000;). Mechanisms for adaptation of simian immunodeficiency virus to replication in alveolar macrophages. J Virol 74: 10852–10859 [CrossRef] [PubMed].
    [Google Scholar]
  25. Norley S., Beer B., Binninger-Schinzel D., Cosma C., Kurth R.. ( 1996;). Protection from pathogenic SIVmac challenge following short-term infection with a nef-deficient attenuated virus. Virology 219: 195–205 [CrossRef] [PubMed].
    [Google Scholar]
  26. Puffer B.A., Pöhlmann S., Edinger A.L., Carlin D., Sanchez M.D., Reitter J., Watry D.D., Fox H.S., Desrosiers R.C., Doms R.W.. ( 2002;). CD4 independence of simian immunodeficiency virus Envs is associated with macrophage tropism, neutralization sensitivity, and attenuated pathogenicity. J Virol 76: 2595–2605 [CrossRef] [PubMed].
    [Google Scholar]
  27. Rud E.W., Cranage M., Yon J., Quirk J., Ogilvie L., Cook N., Webster S., Dennis M., Clarke B.E.. ( 1994;). Molecular and biological characterization of simian immunodeficiency virus macaque strain 32H proviral clones containing nef size variants. J Gen Virol 75: 529–543 [CrossRef] [PubMed].
    [Google Scholar]
  28. Sharma D.P., Zink M.C., Anderson M., Adams R., Clements J.E., Joag S.V., Narayan O.. ( 1992;). Derivation of neurotropic simian immunodeficiency virus from exclusively lymphocytetropic parental virus: pathogenesis of infection in macaques. J Virol 66: 3550–3556 [PubMed].
    [Google Scholar]
  29. Silvera P., Wade-Evans A., Rud E., Hull R., Silvera K., Sangster R., Almond N., Stott J.. ( 2001;). Mechanisms of protection induced by live attenuated simian immunodeficiency virus: III. Viral interference and the role of CD8+T-cells and beta-chemokines in the inhibition of virus infection of PBMCs in vitro. J Med Primatol 30: 1–13 [CrossRef] [PubMed].
    [Google Scholar]
  30. Staprans S.I., Dailey P.J., Rosenthal A., Horton C., Grant R.M., Lerche N., Feinberg M.B.. ( 1999;). Simian immunodeficiency virus disease course is predicted by the extent of virus replication during primary infection. J Virol 73: 4829–4839 [PubMed].
    [Google Scholar]
  31. Stebbings R., Berry N., Stott J., Hull R., Walker B., Lines J., Elsley W., Brown S., Wade-Evans A., other authors. ( 2004;). Vaccination with live attenuated simian immunodeficiency virus for 21 days protects against superinfection. Virology 330: 249–260 [CrossRef] [PubMed].
    [Google Scholar]
  32. Stebbings R., Berry N., Waldmann H., Bird P., Hale G., Stott J., North D., Hull R., Hall J., other authors. ( 2005;). CD8+ lymphocytes do not mediate protection against acute superinfection 20 days after vaccination with a live attenuated simian immunodeficiency virus. J Virol 79: 12264–12272 [CrossRef] [PubMed].
    [Google Scholar]
  33. UNAIDS ( 2013;). Global Report http://www.unaids.org/.
    [Google Scholar]
  34. Watson A., Ranchalis J., Travis B., McClure J., Sutton W., Johnson P.R., Hu S.L., Haigwood N.L.. ( 1997;). Plasma viremia in macaques infected with simian immunodeficiency virus: plasma viral load early in infection predicts survival. J Virol 71: 284–290 [PubMed].
    [Google Scholar]
  35. Williams K.C., Corey S., Westmoreland S.V., Pauley D., Knight H., deBakker C., Alvarez X., Lackner A.A.. ( 2001;). Perivascular macrophages are the primary cell type productively infected by simian immunodeficiency virus in the brains of macaques: implications for the neuropathogenesis of AIDS. J Exp Med 193: 905–915 [CrossRef] [PubMed].
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/vir.0.000135
Loading
/content/journal/jgv/10.1099/vir.0.000135
Loading

Data & Media loading...

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error